Literature DB >> 2079568

Alpha-interferon treatment in Chinese patients with chronic hepatitis B.

A S Lok1, C L Lai, P C Wu, J Y Lau, E K Leung, L S Wong, Y L Fung.   

Abstract

alpha-Interferon has been shown to be the most promising antiviral agent in the treatment of chronic hepatitis B virus infection in Caucasian patients. The experience with recombinant interferon alfa-2a and alfa-2b in four randomized controlled trials in Chinese adults and children is reviewed here. alpha-Interferon alone has little long-term benefit in the treatment of Chinese patients with chronic hepatitis B virus infection, especially in patients who have normal or near normal serum aminotransferase levels. The response in patients with elevated aminotransferase levels appears to be better. The poor antiviral response in patients with normal aminotransferase levels is probably due to immunological tolerance to HBV induced by exposure to the virus in early life. Prednisone pretreatment does not seem to have any additional benefit to using interferon alone in these patients, while the effect in patients with elevated aminotransferase levels remains to be proven.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2079568     DOI: 10.1016/0168-8278(90)90177-s

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

Review 1.  Interferon in the management of chronic hepatitis B.

Authors:  R P Perrillo
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

2.  Serum soluble interleukin-2 receptor levels in patients with chronic hepatitis B virus infection and its relation with anti-HBc.

Authors:  Ping Xiao; Qing-Feng Chen; Yan-Ling Yang; Zhen-Hua Guo; Hong Chen
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

Review 3.  Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B.

Authors:  M T Mellerup; K Krogsgaard; P Mathurin; C Gluud; T Poynard
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.